Abliva AB Year-End Report January – December 2020

2020 summary

KL1333 on its way to registrational Phase 2/3 study⎢Ellen Donnelly appointed new CEO of Abliva.

Important events during 2020


  • Positive feedback from the US Food and Drug Administration (“FDA”) and the UK MHRA, on the clinical development plan.
  • Decision to conduct a cohesive registrational Phase 2/3 study starting in the second half of 2021.
  • The first patients in the Phase 1a/b clinical study were dosed.
  • The first healthy volunteers in the drug-drug interaction study (DDI study) were dosed.


  • Preclinical pharmacology and safety studies entered the final phase.

Strategy and communications

  • Change of company name to Abliva (formerly NeuroVive Pharmaceutical).
  • Virtual Capital Markets Day in June.
  • Mitochondria Day in September.


  • Directed issue of SEK 20 million to Nordic life science investor Hadean Ventures in June. Dr Roger Franklin, partner at Hadean Ventures was elected as Director of Abliva’s Board.
  • A preferential rights issue in May raised approximately SEK 67 million before deduction of issue costs.


  • Magnus Persson left the Board of Directors to focus on his role as founding partner in Eir Ventures.

Important events after the reporting period

  • Ellen Donnelly was appointed new CEO February 3, 2021.
  • The license agreement with Fortify Therapeutics, regarding a development of a local treatment for Leber’s Hereditary Optic Neuropathy (LHON), was terminated.
  • KL1333 phase 1b - seven out of eight patients have been dosed.
  • New date for the Annual General Meeting – 20 May 2021.

Financial information

October-December 2020*

  • Net revenues: KSEK 112 (49)
  • Other operating income: KSEK 1,602 (1,000)
  • Loss before tax: KSEK 13,067 (27,112)
  • Loss per share: SEK 0.04 (0.15)
  • Diluted loss per share: SEK 0.04 (0.15)

January-December 2020

  • Net revenues: KSEK 216 (134)
  • Other operating income: KSEK 1,648 (3,500)
  • Loss before tax: KSEK 59,994 (77,000)
  • Loss per share: SEK 0.24 (0.45)
  • Diluted loss per share: SEK 0.24 (0.45)

* APM Alternative perfomance measures, see definition on page 20.

The complete Year-End report is available for download below and through the Company’s website www.abliva.com

Source: MFN

Det verkar som att du använder en annonsblockerare

Om du är prenumerant behöver du logga in för att fortsätta. Vill bli prenumerant kan du läsa Di Digitalt för 197 kr inkl. moms de första 3 månaderna.

  • Full tillgång till di.se med nyheter och analyser

  • Tillgång till över 1100 aktiekurser i realtid

  • Dagens industri som e-tidning redan kvällen innan

  • Innehållet i alla Di:s appar, tjänster och nyhetsbrev

3 månader för
197 kr
Spara 1000 kr


Redan prenumerant?